 |
 |
|
|
|
|
|
|
|
|
| For Health & Fitness | ||||||||||
|
|
|
|
Various Departments |
A very New concept of treating diabetes is being tried and may be a big boon in medicare for diabetics. INGAP peptide - A peptide called the Islets Neogenesis Associated Protein (INGAP), has been shown to increase the amount of insulin naturally produced by the human body. The INGAP peptide represents a potentially novel anti-diabetic therapy directed at the basis of the disease because it stimulates the growth of insulin-producing cells in the pancreas. This may reduce or even eliminate the need for insulin injections. Research on the INGAP peptide began at the University of Michigan in the early 1980s, when Dr. Vinik and his colleague Dr. Lawrence Rosenberg were unexpectedly able to stimulate the growth of insulin-producing cells in the pancreas of an animal. On December 17, 2001, GMP Companies, Inc. announced that clinical trials would begin at the Texas Diabetes Institute at the University of Texas Health Science Center in San Antonio, the Diabetes Care Center at the University of North Carolina in Chapel Hill and the MedStar Research Institute in Washington, D.C. If the clinical trials are successful, then a drug could be on the market within the decade. According to the Strelitz Diabetes Institutes Web site, further information about participating in the clinical trials can be obtained by calling 954-745-3537.
|
|||||||||
|
See also
|
|
|
|
||
